Aduro Biotech, Inc. has earned a $2 million milestone payment under its worldwide licensing agreement with Merck for work supporting the preparation of an Investigational New Drug Application (IND) for its anti-CD27 antibody. CD27 is a co-stimulatory receptor expressed on different immune cells, such as T-lymphocytes and NK (natural killer) cells. It plays an important role in priming, enhancing and sustaining a productive anti-cancer (CD8 T-cell) adaptive immune response. In preclinical stud...